Saenger P, Schwartz E, Markenson A L, Graziano J H, Levine L S, New M I, Hilgartner M W
J Pediatr. 1980 Feb;96(2):214-8. doi: 10.1016/s0022-3476(80)80805-5.
We have found bioassayable somatomedin activity to be subnormal in 20 of 32 children and adults with beta-thalassemia. The levels were comparable to values reported in growth hormone-deficient subjects. Since patients with thalassemia are not growth hormone deficient, the data suggest the possibility of defective hepatic biosynthesis of somatomedin. Increased iron stores in these patients, who have secondary hemosiderosis of many organs, including the liver, may depress somatomedin activity. Therapy for one year with daily subcutaneous infusions of the iron-chelating agent deferoxamine had no effect on mean bioassayable serum somatomedin activity.
我们发现,在32名β地中海贫血儿童和成人中,有20人的生物活性生长调节素水平低于正常。这些水平与生长激素缺乏患者报告的值相当。由于地中海贫血患者并非生长激素缺乏,这些数据提示生长调节素的肝脏生物合成可能存在缺陷。这些患者存在包括肝脏在内的许多器官继发性含铁血黄素沉着症,铁储存增加可能会抑制生长调节素活性。每天皮下注射铁螯合剂去铁胺进行一年的治疗,对平均生物活性血清生长调节素活性没有影响。